Subcutaneous immunoglobulins
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis
Conditions
Myasthenia Gravis
Trial Timeline
Oct 1, 2011 → Dec 1, 2017
NCT ID
NCT01828294About Subcutaneous immunoglobulins
Subcutaneous immunoglobulins is a phase 1 stage product being developed by CSL for Myasthenia Gravis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01828294. Target conditions include Myasthenia Gravis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01828294 | Phase 1 | Terminated |
Competing Products
20 competing products in Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 76 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |
| zilucoplan (RA101495) + Placebo | UCB | Phase 2 | 49 |